Michelle Rohde
Sangamo BioSciences (United States)(US)
Publications by Year
Research Areas
Virus-based gene therapy research, CRISPR and Genetic Engineering, Lysosomal Storage Disorders Research, CAR-T cell therapy research, Neurogenetic and Muscular Disorders Research
Most-Cited Works
- → TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice(2001)594 cited
- → Robust ZFN-mediated genome editing in adult hemophilic mice(2013)172 cited
- → Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing(2018)125 cited
- → ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome(2018)85 cited
- → Pbx1 is required for Hox D3-mediated angiogenesis(2005)42 cited
- → A sensitive AAV transduction inhibition assay assists evaluation of critical factors for detection and concordance of pre-existing antibodies(2023)12 cited
- → ZFN-mediated genome editing of albumin “safe harbor” in vivo results in supraphysiological levels of human IDS, IDUA and GBA in mice(2015)3 cited
- → 479. ZFN-Mediated In Vivo Genome Editing Results in Supraphysiological Levels of Lysosomal Enzymes Deficient in Hunter and Hurler Syndrome and Gaucher Disease(2015)2 cited
- → 485. ZFN-Mediated Liver-Targeting Gene Therapy Corrects Systemic and Neurological Disease of Mucopolysaccharidosis Type I(2016)1 cited
- → ZFN-mediated in vivo genome editing results in phenotypic correction in murine MPS I and MPS II models(2017)1 cited